ClinicalTrials.gg
Active, not recruitingNCT06425900Updated Jan 21, 2026

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

A Phase 4 interventional study of Winlevi (Clascoterone) cream 1% in Acne Vulgaris, sponsored by Sun Pharmaceutical Industries Limited. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
17th of 19
10 · median 50
Started
2024
with 4 others
Phase 4
7 of 19
1 open now
Registered
11th of 19
by date
Lead sponsor
6 of 19
Sun Pharmaceutical Industries Limited

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 17th largest by enrollment, is one of 5 that started in 2024, is one of 7 in phase 4, and was the 11th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

to compare facial sebaceous gland morphology after 3 months of clascoterone cream 1% treatment and to compare facial sebum constituents at baseline to facial sebum constituents after 3 months of clascoterone cream 1% treatment

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male subjects age 18-35 years.
  2. Subjects of all Fitzpatrick skin types.
  3. Subjects with moderate facial acne and prominent pores indicating sebaceous gland activity.
  4. Subjects with oily facial skin.
  5. Subjects who agree to use only the study product and nothing else to the face.
  6. Subject must possess no scars or tattoos or other confounding dermatologic conditions on the face in the preauricular sites on the left and right face.
  7. Subjects agree not to introduce any new skin care products during the study.
  8. No known medical conditions that, in the investigator's opinion, may interfere with study participation.
  9. Subjects have signed an Form in compliance with 21CFR Part 50: "Protection of Human Subjects."
  10. Subjects are dependable and able to follow directions and willing to comply with the schedule of visits.
  11. Subjects in generally good physical and mental health.

Exclusion criteria

Exclusion Criteria:

  1. Any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics.
  2. Subjects who are not willing to use the assigned study product to their face as instructed.
  3. Subjects who have used any topical prescription products on the face for 4 weeks prior to study entry.
  4. Subjects who have used any OTC products on the face for 2 weeks.
  5. Subjects with unstable medical disorders.
  6. Subjects who are unwilling or unable to comply with the requirements of the protocol.
  7. Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study.
  8. Subjects currently participating in any other clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Winlevi (Clascoterone ) cream 1%

    Drug: Winlevi (Clascoterone) cream 1%

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint is the histologic demonstration of reduced facial sebaceous gland size when comparing baseline to 3 months of clascoterone cream 1 % treatment.

    Time frame: Week 12

Secondary outcomes

  1. The secondary efficacy endpoint is the changes in sebum composition when comparing baseline to 3 months of clascoterone cream 1 % treatment.

    Time frame: Week 12

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2026, 20 months after the start.

Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 23, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06425900
Responsible party
Sponsor
First posted
May 23, 2024
Start date
Jul 1, 2024
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Jan 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion